Home / News
Research breakthroughs, partnerships and key moments. Four streams, one ongoing story.
Milestones
Selective agonists designed in silico with the InVirtuo Platform were independently validated by a CRO, delivering brand-new scaffolds confirmed as real hits - with up to 10x selectivity, EC50 down to 17 nM and Emax of 84%.
Collaborations
InVirtuoLabs secures a EuroHPC JU AI Large Scale Access grant - 2,000,000 GPU-hours (worth ~€3M) on the LUMI-G supercomputer - to advance its AI-driven search for a treatment for MASH, a liver disease affecting roughly 1 in 20 people worldwide with no adequate therapy to date.
Inspirations
A conversation series where scientists and entrepreneurs discuss the ideas, breakthroughs and people shaping the future of drug discovery.
Collaborations
Helsinn provides access to a proprietary compound library while InVirtuoLabs applies InVirtuoGEN to design and optimize novel drug candidates for preclinical development.
Collaborations
Startupticker covers the Eurostars-funded NeuroSpark project, a 36-month initiative advancing AI-driven Virtual Cell Models for neurodegeneration drug research.
Collaborations
A 36-month Eurostars-funded project to develop AI-driven "digital twins" of diseased cells, targeting Spinocerebellar Ataxia Type 3 and broader neurodegenerative disorders.
Breakthroughs
Pretrained checkpoints, benchmarks and reproducible results for InVirtuoGEN released on GitHub — enabling full reproducibility of our state-of-the-art generative chemistry model.
Breakthroughs
InVirtuoGEN surpasses NVIDIA's proprietary model on every benchmark, achieving up to 35% improvement in de novo generation and 20–30% better binding scores in lead optimization.
Breakthroughs
The foundational research behind InVirtuoGEN — a discrete flow generative model that shifts molecular design from completion to refinement. Accepted at the NeurIPS AI for Drug Discovery Workshop.
Inspirations
An interview by the Swiss Startup Association on our founding vision, how AI and physics-based simulations are transforming drug discovery, and what's next for InVirtuoLabs.
Milestones
The Swiss biotech startup closes its first funding round, enabling rapid expansion of the Next Generation Virtual Lab platform and strategic collaborations with pharma partners worldwide.
Milestones
InVirtuoLabs wins first prize at the Boldbrain Startup Challenge, an acceleration program for innovative ideas organized by the Agire Foundation in collaboration with the USI Startup Centre.
Collaborations
InVirtuoLabs is part of ORION, an Innosuisse Flagship project developing an AI-driven microfactory for patient-specific tumor models — enabling personalized cancer therapies and accelerating biomarker discovery, drug development and precision oncology.